Rxwire
In the news · 48h FDA 39 Eli Lilly 19 Roche 9 Merck & Co. (MSD) 8 Johnson & Johnson 4 AbbVie 3 AstraZeneca 3 Novo Nordisk 3
Trials & R&D · first seen yesterday, updated yesterday

Another win in IgAN as Roche’s sefaxersen hits phase III goal

1 outlet Roche

A preview of the next edition of BioWorld, Sept. 23, 2026

Summary from BioWorld Articles.

Coverage 2 articles · 1 outlet

  1. BioWorld Articles
    Another win in IgAN as Roche’s sefaxersen hits phase III goal
  2. BioWorld Articles
    Another win in IgAN as Roche’s sefaxersen hits phase III goal